Extended Data Fig. 9: Assessment of lymphoid and myeloid compartments in CRPC following treatment with ciforadenant +/− anti-PD-1 antibody.

(a-b) (a) Representative flow cytometry plots and (b) quantification showing an increase in the frequency of polyfunctional (IFN-γ⁺TNF-α⁺) CD8⁺ T cells following ciforadenant treatment with or without anti-PD-1 antibody, from the same experiments as in Fig. 5j. (c-d) Quantification of the frequency of (c) CD4⁺ T cells, CD8⁺ T cells, NK cells, and (d) Spp1^hi-TAMs in CRPC developed in Spp1-EGFP mice treated with ciforadenant +/− anti-PD-1 antibody. Treatment groups are indicated as follows: DMSO + isotype antibody (gray; n = 3), DMSO + anti-PD-1 antibody (blue; n = 2), ciforadenant + isotype antibody (olive green; n = 3), and ciforadenant + anti-PD-1 antibody (red; n = 3) (P = 0.049, 0.03, and 0.99 for comparisons between DMSO + isotype vs. ciforadenant + isotype, DMSO + isotype vs. ciforadenant + anti-PD-1, and ciforadenant + isotype vs. ciforadenant + anti-PD-1, respectively). Bars represent the mean + SEM throughout this figure; symbols represent individual mice. Statistical significance was determined by (d) ordinary one-way ANOVA with the Sidak correction; P-values: *<0.05. ns, not significant.